Related Experiment Video
Updated: Nov 24, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Ligong Lu1, Hui Zhang2, Meixiao Zhan3
1Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, 519000, China. luligong1969@126.com.
Abstract:
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients' outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.
Insights
This review covers the critical role of antibody responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 pathogenesis. It discusses antibody therapies and their implications for developing effective COVID-19 vaccines.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a global health crisis with limited effective treatments.
- Host immune responses, particularly humoral immunity involving antibodies, are crucial in determining patient outcomes.
- Antibodies against SARS-CoV-2 can neutralize the virus but may also contribute to disease severity via antibody-dependent enhancement.
Purpose of the Study:
- To review recent advancements in understanding SARS-CoV-2 antibody responses.
- To explore the therapeutic potential of antibodies in treating COVID-19.
- To discuss the implications of these findings for COVID-19 vaccine development.
Main Methods:
- Literature review of studies on SARS-CoV-2 antibody responses.
- Analysis of clinical data on antibody therapies like convalescent plasma and immunoglobulin products.
- Examination of research on monoclonal neutralizing antibodies and vaccine candidates.
Main Results:
- Characterization of diverse antibody responses in different populations.
- Evaluation of the efficacy and safety of antibody-based treatments.
- Assessment of early clinical results from COVID-19 vaccine trials.
Conclusions:
- Antibody responses are central to both protection against and pathogenesis of COVID-19.
- Therapeutic strategies involving antibodies show promise but require further investigation.
- Understanding antibody dynamics is essential for the successful development of SARS-CoV-2 vaccines.
Related Concept Videos
00:42Cross-reactivity
01:51Vaccinations
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:36Humoral Immune Responses
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...